Obsidian Therapeutics (NASDAQ:OBX – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.
A number of other equities research analysts have also recently issued reports on OBX. Zacks Research raised shares of Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. TD Cowen assumed coverage on Obsidian Therapeutics in a report on Thursday, August 6th. They issued a “buy” rating for the company. Lifesci Capital initiated coverage on Obsidian Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price target for the company. Weiss Ratings assumed coverage on Obsidian Therapeutics in a research note on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. Finally, Piper Sandler assumed coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They set an “overweight” rating and a $42.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.00.
Obsidian Therapeutics Trading Up 0.6%
Shares of Obsidian Therapeutics stock opened at $12.56 on Friday. Obsidian Therapeutics has a 52-week low of $9.60 and a 52-week high of $49.97. The firm has a 50-day moving average price of $14.28.
Obsidian Therapeutics (NASDAQ:OBX – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.80). As a group, sell-side analysts forecast that Obsidian Therapeutics will post -1.81 EPS for the current year.
Obsidian Therapeutics Company Profile
Obsidian Therapeutics is a biotechnology company developing engineered cell therapies for cancer. Its research focuses on modifying immune cells to improve their ability to target tumors and function within the body. The company’s programs include OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) therapy being developed for solid tumors. Obsidian’s cytoDRiVE platform is designed to regulate the activity of therapeutic proteins using small molecules, with the aim of controlling and optimizing cell therapies.
See Also
- Five stocks we like better than Obsidian Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Obsidian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obsidian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
